Cargando…

Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis

PURPOSE: Breast cancer is a heterogeneous disease usually including four molecular subtypes such as luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC). TNBC is more aggressive than other breast cancer subtypes. Despite major advances in ER-positive or HER2-amplified breast...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jinsong, Yang, Jianbo, Chen, Weicai, Wu, Huisheng, Yuan, Zishan, Wang, Kun, Li, Guojin, Sun, Jie, Yu, Limin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478040/
https://www.ncbi.nlm.nih.gov/pubmed/26103053
http://dx.doi.org/10.1371/journal.pone.0129842
_version_ 1782377846540337152
author He, Jinsong
Yang, Jianbo
Chen, Weicai
Wu, Huisheng
Yuan, Zishan
Wang, Kun
Li, Guojin
Sun, Jie
Yu, Limin
author_facet He, Jinsong
Yang, Jianbo
Chen, Weicai
Wu, Huisheng
Yuan, Zishan
Wang, Kun
Li, Guojin
Sun, Jie
Yu, Limin
author_sort He, Jinsong
collection PubMed
description PURPOSE: Breast cancer is a heterogeneous disease usually including four molecular subtypes such as luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC). TNBC is more aggressive than other breast cancer subtypes. Despite major advances in ER-positive or HER2-amplified breast cancer, there is no targeted agent currently available for TNBC, so it is urgent to identify new potential therapeutic targets for TNBC. METHODS: We first used microarray analysis to compare gene expression profiling between TNBC and non-TNBC. Furthermore an integrated analysis was conducted based on our own and published data, leading to more robust, reproducible and accurate predictions. Additionally, we performed qRT-PCR in breast cancer cell lines to verify the findings in integrated analysis. RESULTS: After searching Gene Expression Omnibus database (GEO), two microarray studies were obtained according to the inclusion criteria. The integrated analysis was conducted, including 30 samples of TNBC and 77 samples of non-TNBC. 556 genes were found to be consistently differentially expressed (344 up-regulated genes and 212 down-regulated genes in TNBC). Functional annotation for these differentially expressed genes (DEGs) showed that the most significantly enriched Gene Ontology (GO) term for molecular functions was protein binding (GO: 0005515, P = 6.09E-21), while that for biological processes was signal transduction (GO: 0007165, P = 9.46E-08), and that for cellular component was cytoplasm (GO: 0005737, P = 2.09E-21). The most significant pathway was Pathways in cancer (P = 6.54E-05) based on Kyoto Encyclopedia of Genes and Genomes (KEGG). DUSP1 (Degree = 21), MYEOV2 (Degree = 15) and UQCRQ (Degree = 14) were identified as the significant hub proteins in the protein-protein interaction (PPI) network. Five genes were selected to perform qRT-PCR in seven breast cancer cell lines, and qRT-PCR results showed that the expression pattern of selected genes in TNBC lines and non-TNBC lines was nearly consistent with that in the integrated analysis. CONCLUSION: This study may help to understand the pathogenesis of different breast cancer subtypes, contributing to the successful identification of therapeutic targets for TNBC.
format Online
Article
Text
id pubmed-4478040
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44780402015-07-02 Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis He, Jinsong Yang, Jianbo Chen, Weicai Wu, Huisheng Yuan, Zishan Wang, Kun Li, Guojin Sun, Jie Yu, Limin PLoS One Research Article PURPOSE: Breast cancer is a heterogeneous disease usually including four molecular subtypes such as luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC). TNBC is more aggressive than other breast cancer subtypes. Despite major advances in ER-positive or HER2-amplified breast cancer, there is no targeted agent currently available for TNBC, so it is urgent to identify new potential therapeutic targets for TNBC. METHODS: We first used microarray analysis to compare gene expression profiling between TNBC and non-TNBC. Furthermore an integrated analysis was conducted based on our own and published data, leading to more robust, reproducible and accurate predictions. Additionally, we performed qRT-PCR in breast cancer cell lines to verify the findings in integrated analysis. RESULTS: After searching Gene Expression Omnibus database (GEO), two microarray studies were obtained according to the inclusion criteria. The integrated analysis was conducted, including 30 samples of TNBC and 77 samples of non-TNBC. 556 genes were found to be consistently differentially expressed (344 up-regulated genes and 212 down-regulated genes in TNBC). Functional annotation for these differentially expressed genes (DEGs) showed that the most significantly enriched Gene Ontology (GO) term for molecular functions was protein binding (GO: 0005515, P = 6.09E-21), while that for biological processes was signal transduction (GO: 0007165, P = 9.46E-08), and that for cellular component was cytoplasm (GO: 0005737, P = 2.09E-21). The most significant pathway was Pathways in cancer (P = 6.54E-05) based on Kyoto Encyclopedia of Genes and Genomes (KEGG). DUSP1 (Degree = 21), MYEOV2 (Degree = 15) and UQCRQ (Degree = 14) were identified as the significant hub proteins in the protein-protein interaction (PPI) network. Five genes were selected to perform qRT-PCR in seven breast cancer cell lines, and qRT-PCR results showed that the expression pattern of selected genes in TNBC lines and non-TNBC lines was nearly consistent with that in the integrated analysis. CONCLUSION: This study may help to understand the pathogenesis of different breast cancer subtypes, contributing to the successful identification of therapeutic targets for TNBC. Public Library of Science 2015-06-23 /pmc/articles/PMC4478040/ /pubmed/26103053 http://dx.doi.org/10.1371/journal.pone.0129842 Text en © 2015 He et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
He, Jinsong
Yang, Jianbo
Chen, Weicai
Wu, Huisheng
Yuan, Zishan
Wang, Kun
Li, Guojin
Sun, Jie
Yu, Limin
Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis
title Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis
title_full Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis
title_fullStr Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis
title_full_unstemmed Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis
title_short Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis
title_sort molecular features of triple negative breast cancer: microarray evidence and further integrated analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478040/
https://www.ncbi.nlm.nih.gov/pubmed/26103053
http://dx.doi.org/10.1371/journal.pone.0129842
work_keys_str_mv AT hejinsong molecularfeaturesoftriplenegativebreastcancermicroarrayevidenceandfurtherintegratedanalysis
AT yangjianbo molecularfeaturesoftriplenegativebreastcancermicroarrayevidenceandfurtherintegratedanalysis
AT chenweicai molecularfeaturesoftriplenegativebreastcancermicroarrayevidenceandfurtherintegratedanalysis
AT wuhuisheng molecularfeaturesoftriplenegativebreastcancermicroarrayevidenceandfurtherintegratedanalysis
AT yuanzishan molecularfeaturesoftriplenegativebreastcancermicroarrayevidenceandfurtherintegratedanalysis
AT wangkun molecularfeaturesoftriplenegativebreastcancermicroarrayevidenceandfurtherintegratedanalysis
AT liguojin molecularfeaturesoftriplenegativebreastcancermicroarrayevidenceandfurtherintegratedanalysis
AT sunjie molecularfeaturesoftriplenegativebreastcancermicroarrayevidenceandfurtherintegratedanalysis
AT yulimin molecularfeaturesoftriplenegativebreastcancermicroarrayevidenceandfurtherintegratedanalysis